The popular weight loss drugs have also been found to reduce other risks, including the risk of death from COVID-19.
The study found that semaglutide, sold under brand names Ozempic and Wegovy reduced the hospitalization risk by 22% in alcoholic patients. Ozempic had earlier been shown to mitigate joint pain.